Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Taiwan Semiconductor Mfg. Co. Ltd. (TSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Taiwan Semiconductor Mfg. Co. Ltd. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while Taiwan Semiconductor Mfg. Co. Ltd. trades at $427.11 (market cap $1.91T). The key difference: Taiwan Semiconductor Mfg. Co. Ltd. is far larger — about 377.5× ACADIA Pharmaceuticals Inc.'s market cap, and Taiwan Semiconductor Mfg. Co. Ltd. pays a 0.91% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | TSM | |
|---|---|---|
Market Cap | $5.06B | $1.91T |
Sector | Health | Technology |
52-Week High | $29.41 | $477.57 |
52-Week Low | $20.06 | $227.33 |
Enterprise Value | $4.18B | $1.84T |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.21, up 2.67% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.18 versus $0.07 expected, driven by robust Daybue and Nuplazid sales, leading to a raised 2026 revenue outlook. The stock shows high profitability with a net margin of 33.42% and ROE of 35.74%, though valuation metrics like EV/EBITDA of 42.2 indicate premium pricing.
The outlook is positive with 70% analyst buy ratings and a $33 consensus target, but risks include reliance on key drugs and Phase 2 trial results for remlifanserin due by October 2026. Cash flow volatility from heavy investing outlays in 2025 warrants monitoring, but operational strength supports growth potential.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Taiwan Semiconductor Mfg. Co. Ltd.
Taiwan Semiconductor Manufacturing Company, or TSMC, is the world's largest dedicated chip foundry, with over 57% market share in 2021 per Gartner. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the U.S. in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs.
Read more on TSM →
